Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001610618-25-000010
Filing Date
2025-02-26
Accepted
2025-02-26 18:24:46
Documents
2
Period of Report
2025-02-24

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1740612281.html 3  
1 FORM 3 wk-form3_1740612281.xml 3 1709
2 POWER OF ATTORNEY fkpoa.htm EX-24 6631
  Complete submission text file 0001610618-25-000010.txt   9951
Mailing Address C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Business Address
KARBE FRANK (Reporting) CIK: 0001276700 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36912 | Film No.: 25671954

Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Issuer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)